Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Cell-Based HTS of HIV-1 Protease Autoprocessing: New Drug Di
2026-05-21
This study introduces a robust cell-based AlphaLISA assay for high-throughput screening of inhibitors targeting HIV-1 protease autoprocessing. By enabling precise evaluation of both drug efficacy and resistance, the platform advances our understanding of protease inhibition and supports translational research in antiviral drug development.
-
Butyrate-Induced Ferroptosis Suppresses Lung Cancer Stemness
2026-05-21
This study reveals that butyrate reduces lung cancer stem cell characteristics by triggering ferroptosis through lysosomal Fe2+ accumulation and SLC7A11 degradation. The findings highlight a novel metabolic vulnerability in lung cancer stem cells and suggest new strategies for targeting tumor progression.
-
Aminopeptidase Inhibition Specificity: Insights for ACE Inhi
2026-05-20
This article examines the re-evaluation of various metallopeptidase inhibitors, including ACE inhibitors, on mammalian cell surface aminopeptidases, based on the reference study. The work clarifies the selectivity profiles of these inhibitors and informs experimental design for disease models involving the renin-angiotensin system and related peptidase pathways.
-
Itraconazole: Advanced Workflows for Candida Resistance Mode
2026-05-20
Itraconazole is redefining Candida research by targeting both fungal metabolism and cellular signaling pathways. This article delivers a stepwise protocol, troubleshooting insights, and actionable guidance for leveraging this triazole antifungal agent in drug resistance and biofilm assays.
-
Angiotensin II Drives M1 Macrophage Polarization via Cx43/NF
2026-05-19
This study uncovers how Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) drives RAW264.7 macrophages toward a pro-inflammatory M1 phenotype through the connexin 43/NF-κB pathway, using a robust panel of molecular assays. The findings clarify a critical mechanism linking Angiotensin II to vascular inflammation and provide actionable targets for cardiovascular remodeling and hypertension mechanism research.
-
SAR131675: Benchmark VEGFR-3 Inhibitor for Fibrosis and Tumo
2026-05-19
SAR131675 empowers researchers to dissect VEGFC/VEGFD pathways with nanomolar precision, offering selective inhibition for advanced lymphangiogenesis and tumor growth studies. Its rigorous selectivity, robust in vivo efficacy, and recent application in NASH fibrosis models make it a gold-standard anti-lymphangiogenic agent for translational research.
-
Mitofusin 2 Regulates Angiotensin II-Induced Endothelial Sen
2026-05-18
This study uncovers how Angiotensin II drives endothelial cell aging by activating the STAT3–BCL6 axis, leading to reduced MFN2 and mitochondrial dysfunction. The findings clarify molecular links between vascular aging and hypertension, highlighting MFN2 as a potential therapeutic target.
-
BMS 309403: Optimizing FABP4 Inhibitor Workflows in Atherosc
2026-05-18
BMS 309403 empowers researchers to dissect the role of FABP4 in atherosclerosis and metabolic disease with nanomolar precision. This article delivers data-driven protocol enhancements, troubleshooting strategies, and translational insights for deploying BMS 309403 in foam cell, inflammation, and lipid metabolism studies.
-
Tubastatin A: Precision HDAC6 Inhibition in Cardiac Injury M
2026-05-17
Discover how Tubastatin A, a potent HDAC6 inhibitor, advances cardiac injury modeling by targeting cell death pathways. This article uniquely explores its mechanistic roles and translational impact, with new insights beyond cancer biology.
-
Methotrexate’s Methylation Nexus: Folate Antagonist in CNS R
2026-05-16
Explore how methotrexate, a leading folate antagonist, uniquely impacts CNS methylation pathways and immunosuppressive mechanisms. This article uncovers new experimental insights and practical assay implications for researchers.
-
DiscoveryProbe Protease Inhibitor Library: Precision Tools f
2026-05-15
Explore how the DiscoveryProbe Protease Inhibitor Library empowers researchers to dissect protease pathways, address drug resistance, and enhance screening assay design. This article uniquely bridges reference-driven insights with practical assay optimization.
-
Tetracycline C6589: Data-Driven Solutions for Lab Assay Reli
2026-05-15
This article provides evidence-based guidance for biomedical researchers and lab technicians evaluating Tetracycline (SKU C6589) as a broad-spectrum polyketide antibiotic. By addressing real-world assay challenges—ranging from antibiotic selection to reproducibility and protocol optimization—it demonstrates how Tetracycline from APExBIO supports reliable, high-quality experimental results.
-
Reliable ARCA Capped mRNA Synthesis: HyperScribe™ Kit Plus 1
2026-05-14
This article addresses persistent challenges in modified mRNA production for cell-based assays and RNA vaccine development, emphasizing how the HyperScribe™ All in One mRNA Synthesis Kit Plus 1 (ARCA, 5mCTP, ψUTP, T7, poly(A)), SKU K1064, delivers robust, reproducible results. Scenario-driven analysis highlights key protocol optimizations, immune-evasion strategies, and vendor selection considerations for biomedical researchers.
-
CX-5461: Defining Selectivity and Mechanistic Precision in R
2026-05-14
Discover how CX-5461, a leading RNA polymerase I inhibitor, sets a new benchmark in cancer research with its unique selectivity and mechanistic insights. This article explores advanced applications, protocol precision, and evidence-driven guidance for maximizing its impact in translational oncology.
-
Puromycin Aminonucleoside: Mechanistic Benchmarks for Podocy
2026-05-13
Puromycin aminonucleoside is a validated nephrotoxic agent for inducing podocyte injury and glomerular lesions in preclinical nephrotic syndrome research. As the aminonucleoside moiety of puromycin, it enables precise, reproducible models of proteinuria and FSGS. This article details its mechanisms, evidence, and best practices for integration into renal pathology workflows.